PMC:4310921 / 329-648 JSONTXT

{"project":"NEUROSES","denotations":[{"id":"T40","span":{"begin":130,"end":141},"obj":"CHEBI_8871"},{"id":"T46","span":{"begin":312,"end":318},"obj":"CHEBI_18059"},{"id":"T52","span":{"begin":241,"end":250},"obj":"CHEBI_81580"},{"id":"T58","span":{"begin":270,"end":277},"obj":"CHEBI_46217"},{"id":"T59","span":{"begin":270,"end":277},"obj":"CHEBI_16977"},{"id":"T60","span":{"begin":270,"end":277},"obj":"CHEBI_16449"},{"id":"T61","span":{"begin":292,"end":295},"obj":"CHEBI_37708"}],"text":"Methods\nTwenty-five children and adolescents [aged 7-18 years, 12.1±3.3 years (mean±SD); 19 boys and 6 girls] who had been taking risperidone for at least 3 months were enrolled. The following blood parameters were measured: serum levels of prolactin, thyroid hormones, alanine transaminase (ALT), sex hormones, lipids."}